Overview

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
Phase:
Phase 1
Details
Lead Sponsor:
Yana Najjar
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Metformin
Pembrolizumab